Estrella Immunopharma Statistics
Total Valuation
ESLA has a market cap or net worth of $39.65 million. The enterprise value is $34.92 million.
| Market Cap | 39.65M |
| Enterprise Value | 34.92M |
Important Dates
The next estimated earnings date is Friday, August 2, 2024, before market open.
| Earnings Date | Aug 2, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ESLA has 36.38 million shares outstanding. The number of shares has increased by 10,431.23% in one year.
| Shares Outstanding | 36.38M |
| Shares Change (YoY) | +10,431.23% |
| Shares Change (QoQ) | +0.90% |
| Owned by Insiders (%) | 77.05% |
| Owned by Institutions (%) | 0.82% |
| Float | 9.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.67 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 62.34, with zero debt.
| Current Ratio | 62.34 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -153.60% and return on invested capital (ROIC) is -71.72%.
| Return on Equity (ROE) | -153.60% |
| Return on Assets (ROA) | -50.30% |
| Return on Capital (ROIC) | -71.72% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -89.99% in the last 52 weeks. The beta is 0.08, so ESLA's price volatility has been lower than the market average.
| Beta (5Y) | 0.08 |
| 52-Week Price Change | -89.99% |
| 50-Day Moving Average | 0.99 |
| 200-Day Moving Average | 1.78 |
| Relative Strength Index (RSI) | 62.72 |
| Average Volume (20 Days) | 12,226 |
Short Selling Information
The latest short interest is 11,011, so 0.03% of the outstanding shares have been sold short.
| Short Interest | 11,011 |
| Short Previous Month | 10,858 |
| Short % of Shares Out | 0.03% |
| Short % of Float | 0.12% |
| Short Ratio (days to cover) | 0.29 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -6.09M |
| Pretax Income | -6.09M |
| Net Income | -6.09M |
| EBITDA | -6.11M |
| EBIT | -6.09M |
| Earnings Per Share (EPS) | -$0.95 |
Balance Sheet
The company has $4.73 million in cash and no debt, giving a net cash position of $4.73 million or $0.13 per share.
| Cash & Cash Equivalents | 4.73M |
| Total Debt | n/a |
| Net Cash | 4.73M |
| Net Cash Per Share | $0.13 |
| Equity (Book Value) | 8.49M |
| Book Value Per Share | 0.23 |
| Working Capital | 8.49M |
Cash Flow
| Operating Cash Flow | -15.82M |
| Capital Expenditures | n/a |
| Free Cash Flow | -15.82M |
| FCF Per Share | -$0.45 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ESLA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10,431.23% |
| Shareholder Yield | -10,431.23% |
| Earnings Yield | -15.36% |
| FCF Yield | -39.90% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |